and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852– 1448, 301–827–0379.

SUPPLEMENTARY INFORMATION: In the Federal Register of May 15, 1995 (60 FR 25920), FDA announced the establishment and first meeting of CBER's standing oversight committee. As explained in the notice, the importance to the public health of getting new biological products on the market as efficiently as possible has made improving the biological product evaluation process an FDA priority. CBER's managed review process focuses on specific milestones or intermediate goals to ensure that a quality review is conducted within a specified time period. CBER's RTF oversight committee meetings continue CBER's effort to promote the timely, efficient, and consistent review of PLA's and

FDA regulations on filing PLA's and ELA's are found in 21 CFR 601.2 and 601.3. A sponsor who receives an RTF notification may request an informal conference with CBER, and thereafter may ask that the application be filed over protest, similar to the procedure for drugs described under 21 CFR 314.101(a)(3).

CBER's standing RTF oversight committee consists of senior CBER officials, a senior official from the FDA's Center for Drug Evaluation and Research, and FDA's Chief Mediator and Ombudsman. Meetings will ordinarily be held once a quarter to review all of the RTF decisions. The purpose of such a review is to assess the consistency within CBER in rendering RTF decisions.

Because the committee's deliberations will deal with confidential commercial information, all meetings will be closed to the public. The committee's deliberations will be reported in the minutes of the meeting. Although those minutes will not be publicly available because they will contain confidential commercial information, summaries of the committee's deliberations, with all confidential commercial information omitted, may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. If, following the committee's review, an RTF decision changes, the appropriate division within CBER will notify the sponsor.

Dated: September 26, 1996. William K. Hubbard, Associate Commissioner for Policy Coordination. [FR Doc. 96–25600 Filed 10–04–96; 8:45 am]

BILLING CODE 4160-01-F

### Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A–54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443–6014.

#### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must

participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615–331–5300.

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931/205–263–5745.

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703–802–6900.

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702– 733–7866.

Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801– 583–2787.

Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–227–2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414–355–4444/800–877–7016.

Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305–325–5810.

Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310–215– 6020.

Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800–445–6917.

CompuChem Laboratories, Inc., 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–549–8263/800– 833–3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group).

CORNING Clinical Laboratories, 4771 Regent Blvd., Irving, TX 75063, 800– 526–0947 (formerly: Damon Clinical Laboratories, Damon/MetPath).

CORNING Clinical Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220–3610, 800–284–

- 7515 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories).
- CORNING Clinical Laboratories, 4444 Giddings Road, Auburn Hills, MI 48326, 800–444–0106/810–373–9120 (formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath).
- CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 630–595–3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories).
- CORNING Clinical Laboratories, South Central Divison, 2320 Schuetz Rd., St. Louis, MO 63146, 800–288–7293 (formerly: Metropolitan Reference Laboratories, Inc.).
- CORNING Clinical Laboratory, One Malcolm Ave., Teterboro, NJ 07608, 201–393–5000 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories).
- CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410–536–1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science).
- CORNING Clinical Laboratories, 7470–A Mission Valley Rd., San Diego, CA 92108–4406, 800–446–4728/619–686–3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute).
- Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800– 876–3652/417–269–3093 (formerly: Cox Medical Centers).
- Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, P.O. Box 88–6819, Great Lakes, IL 60088–6819, 847–688–2045/847–688–4171.
- Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 941–936–5446/800–735–5416.
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912–244–4468.
- DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800–898–0180/206–386–2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).
- DrugScan, Inc., P.O. Box 2969, 1119Mearns Rd., Warminster, PA 18974, 215–674–9310.
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601–236– 2609.

- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608– 267–6267.
- Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800–725–3784/915–563–3300 (formerly: Harrison & Associates Forensic Laboratories).
- Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513–569–2051.
- LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913–888–3927 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.).
- Laboratory Corporation of America, 21903 68th Ave. South, Kent, WA 98032, 206–395–4000 (formerly: Regional Toxicology Services).
- Laboratory Corporation of America Holdings, 1120 Stateline Rd., Southaven, MS 38671, 601–342–1286 (formerly: Roche Biomedical Laboratories, Inc.).
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800–437–4986 (formerly: Roche Biomedical Laboratories, Inc.).
- Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504–392–7961.
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715– 389–3734/800–331–3734.
- MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38175, 901–795–1515.
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699–0008, 419–381–5213.
- Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302–655–5227.
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800–832–3244/612–636–7466.
- Methodist Hospital of Indiana, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317– 929–3587.
- Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800–752–1835/309– 671–5199.
- MetroLab-Legacy Laboratory Services, 235 N. Graham St., Portland, OR 97227, 503–413–4512, 800–237–7808 (x4512).
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612– 725–2088.

- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805–322–4250.
- Northwest Toxicology, Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 800–322–3361.
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2134.
- Pathology Associates Medical Laboratories, East 11604 Indiana, Spokane, WA 99206, 509–926–2400/ 800–541–7891.
- PharmChem Laboratories, Inc., 1505–A O'Brien Dr., Menlo Park, CA 94025, 415–328–6200/800–446–5177.
- PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817–595–0294 (formerly: Harris Medical Laboratory).
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–338–4070/800–821–3627.
- Poisonlab, Inc., 7272 Clairemont Mesa Rd., San Diego, CA 92111, 619–279– 2600/800–882–7272.
- Premier Analytical Laboratories, 15201 I–10 East, Suite 125, Channelview, TX 77530, 713–457–3784 (formerly: Drug Labs of Texas).
- Presbyterian Laboratory Services, 1851 East Third Street, Charlotte, NC 28204, 800–473–6640.
- Puckett Laboratory, 4200 Mamie St., Hattiesburgh, MS 39402, 601–264–3856/800–844–8378.
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804–378–9130.
- Scott & White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 800–749–3788.
- S.E.D. Medical Laboratories, 500 Walter NE, Suite 500, Albuquerque, NM 87102, 505–244–8800, 800–999– LABS.
- Sierra Nevada Laboratories, Inc., 888 Willow St., Reno, NV 89502, 702– 334–3400.
- SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91045, 818–989–2520.
- SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 352–787–9006, (formerly: Doctors & Physicians Laboratory).
- SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590 (formerly: SmithKline Bio-Science Laboratories).
- SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 847–885– 2010, (formerly: International Toxicology Laboratories).

SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800–523–5447 / 610–631–4600 (formerly: SmithKline Bio-Science Laboratories).

SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214–638–1301, (formerly: SmithKline Bio-Science Laboratories).

South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219–234–4176,

Southwest Laboratories, 2727 W. Baseline Rd., Suite 6, Tempe, AZ 85283, 602–438–8507.

St. Anthony Hospital (Toxicology Laboratory), P.O. Box 205, 1000 N. Lee St., Oklahoma City, OK 73102, 405–272–7052.

Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573–882–1273.

Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305–593–2260.

TOXWORX Laboratories, Inc., 6160 Variel Ave., Woodland Hills, CA 91367, 818–226–4373 (formerly: Laboratory Specialists, Inc.; Abused Drug Laboratories; MedTox Bio-Analytical, a Division of MedTox Laboratories, Inc.).

UNILAB, 18408 Oxnard St., Tarzana, CA 91356, 800–492–0800/818–343– 8191 (formerly: MetWest-BPL Toxicology Laboratory).

UTMB Pathology-Toxicology Laboratory, University of Texas Medical Branch, Clinical Chemistry Division, 301 University Boulevard, Room 5.158, Old John Sealy, Galveston, Texas 77555–0551, 409– 772–3197.

The following laboratory withdrew from the National Laboratory Certification Program on September 22, 1996: Laboratory Corporation of America, 13900 Park Center Rd., Herndon, VA 22071, 703–742–3100. (Formerly: National Health Laboratories Incorporated).

Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration. [FR Doc. 96–25719 Filed 10–4–96; 8:45 am]

BILLING CODE 4160-20-U

#### **DEPARTMENT OF THE INTERIOR**

## **Bureau of Land Management**

[ID-014-06-1220-00]

## Confluence Recreation Site Camping Closure and No Fires Notice

**AGENCY:** Bureau of Land Management, Interior.

ACTION: Notice.

**SUMMARY:** Notice is hereby given that effective immediately, the undeveloped site in the Cascade Resource Area known as the Confluence Recreation Site is closed to camping and open fires. The closed area is generally described as follows.

At the confluence of the Payette River (Middle Fork) with the Payette River (South Fork) approximately 3 miles west of Garden Valley on the Garden Valley Road (Highway 17), Boise County, Idaho, T.9N., R.4E. Section 20, lot 1 and lot 2, Boise Meridian, Idaho.

FOR FURTHER INFORMATION CONTACT: John Fend, Area Manager, 3948 Development Avenue, Boise, Idaho 83705, telephone (208) 384–3000.

**SUPPLEMENTARY INFORMATION: Past** camping of this small undeveloped site has caused considerable confrontation with users and with residents of an adjacent developed residential area. Recreation users trespass across a private road and bridge to gain vehicular access to the peninsula portion of the site. This portion is very small, less than two acres, and has no sanitation facility. Open fires pose a safety hazard to the neighboring development. The site contains mixed ponderosa pine, shrubs, perennial and annual grasses. The area drys out early in the summer season and contains easily ignitable fire fuels. The intended effect of this action is to eliminate degradation by campers, and reduce the possibility of accidental wildfire and threat to the neighboring development. Day use access from river to peninsula and river and road access to northern parcel will continue. Camping closure and no fires signs will be posted at the

The authority for this closure is 43 CFR 8364.1. The closure is in conformance with the Cascade Resource Management Plan. It will remain in effect until rescinded or modified by the authorized officer.

Thomas M. Woodward, Acting Cascade Resource Area Manager. [FR Doc. 96–25564 Filed 10–4–96; 8:45 am]

BILLING CODE 4310-GG-M

[ID-010-06-2822-00-F284]

# Eighth Street Fire In Ada County, ID; Emergency Closure

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Emergency closure of roads, trails and all cross-country travel to pedestrians, equestrians, motorized vehicles, bicycles on BLM-administered lands with the perimeter of the Eighth Fire in Ada County, Idaho.

**SUMMARY:** All types of travel, pedestrians, equestrians, motorized vehicles, and bicycles are limited to roads and trails that are marked or posted open on pubic lands administered by the Bureau of Land Management within the boundaries of the Eighth Street Fire in Ada County, Idaho to protect the public from the exposed hazards, and to reduce erosion to soil and watershed. The area is roughly bounded by the Boise City on the southwest, Bogus Basin Road on the northwest, Rocky Canyon on the southeast and the Boise Ridge Road on the northeast.

The closure will be in effect immediately and will expire September 30, 1998, unless the authorized officer determines that the safety hazards still present a danger to users or the soil and vegetation within the burned area are insufficiently stabilized to sustain traffic. Exception to this closure, which will be posted, include vehicle use for administrative and emergency purposes. Under special circumstances, and upon request, the authorized officer may issue a permit allowing vehicle access into the area for other purposes, on a caseby-case basis. Along the perimeter of the fire, only the Rocky Canyon, Bogus Basin, and Boise Ridge Roads will remain open to vehicle traffic. All traffic on the Rocky Canyon, Bogus Basin, and Boise Ridge Roads will be confined to the roadbed and will not be permitted to travel off the road into the fire area unless the roads and trails are marked or posted open.

## Definitions

(a) "Public Lands" mean any lands or interest in lands owned by the United States and administered by the Bureau of Land Management.

(b) "Authorized Officer" means an employee of the Bureau of Land Management who has been delegated the authority to perform under title 43.

(c) "Emergency purpose" means any military, fire, or law enforcement action requiring the use of vehicles within the burn area.

(d) "Administrative purpose" refers to action of an employee, agent, or